• Inborn errors of metabolism

Vimizim Generic Name & Formulations

General Description

Elosulfase alfa 1mg/mL; soln for IV infusion; preservative-free.

Pharmacological Class

Hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme.

How Supplied

Single-use vial (5mL)—1

Vimizim Indications


Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).

Vimizim Dosage and Administration

Adults and Children

<5yrs: not established. Give by IV infusion over 3.5–4.5 hours based on infusion volume. ≥5yrs: 2mg/kg once weekly. Pre-treat with antihistamines with or without antipyretics 30–60 mins prior to infusion.

Vimizim Contraindications

Not Applicable

Vimizim Boxed Warnings

Boxed Warning

Risk of anaphylaxis.

Vimizim Warnings/Precautions


Risk of serious anaphylactic reactions; observe patients during and after administration. Have epinephrine inj available. Discontinue immediately if severe hypersensitivity reactions occur. Acute febrile or respiratory illness; evaluate clinical status prior to therapy and consider delaying infusion. Risk of sleep apnea; consider evaluating airway patency prior to initiation. Have supplemental oxygen or continuous positive airway pressure available. Monitor for signs/symptoms of spinal or cervical cord compression. Pregnancy. Nursing mothers.

Vimizim Pharmacokinetics

See Literature

Vimizim Interactions

Not Applicable

Vimizim Adverse Reactions

Adverse Reactions

Pyrexia, vomiting, headache, nausea, abdominal pain, chills, fatigue; sleep apnea, anaphylaxis, possible antibody formation.

Vimizim Clinical Trials

See Literature

Vimizim Note


To enroll in the Morquio A Registry for monitoring effects of Vimizim contact [email protected] or call (800) 983-4587.

Vimizim Patient Counseling

See Literature